The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies.
Publication/Presentation Date
4-1-2022
Abstract
The majority of contemporary allogeneic hematopoietic stem cell transplantation (HCT) procedures utilize partially HLA-mismatched stem cell grafts. Donor-specific anti-HLA antibodies (DSA) are associated with primary graft failure independent of the graft source, conditioning intensity and other patient and donor factors. Here we provide an update on testing and monitoring of DSA, review the impact of DSA on stem cell engraftment, and present promising desensitization modalities. Ultimately, we attempt to provide practical recommendations for DSA screening and mitigation strategies.
Volume
57
Issue
4
First Page
526
Last Page
531
ISSN
1476-5365
Published In/Presented At
File, B., Huang, Y., Peedin, A., & Gergis, U. (2022). The impact of HLA donor-specific antibodies on engraftment and the evolving desensitization strategies. Bone marrow transplantation, 57(4), 526–531. https://doi.org/10.1038/s41409-022-01578-w
Disciplines
Medicine and Health Sciences
PubMedID
35082370
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article